Smad7 sensitizes A549 lung cancer cells to cisplatin-induced apoptosis through heme oxygenase-1 inhibition

2012 ◽  
Vol 420 (2) ◽  
pp. 288-292 ◽  
Author(s):  
Woo-Kwang Jeon ◽  
Hey-Young Hong ◽  
Won-Chan Seo ◽  
Kyu-Hyoung Lim ◽  
Hui-Young Lee ◽  
...  
2007 ◽  
Vol 62 (1) ◽  
pp. 33 ◽  
Author(s):  
So-Young Kim ◽  
Eun-Jung Kim ◽  
Hye-Yeon Jang ◽  
Ki-Eun Hwang ◽  
Jung-Hyun Park ◽  
...  

2006 ◽  
Vol 5 (1) ◽  
pp. 39
Author(s):  
Hak-Ryul Kim ◽  
Eun-Jung Kim ◽  
Ki-Eun Hwang ◽  
So-Young Kim ◽  
Seong-Hoon Park ◽  
...  

2008 ◽  
Vol 46 (12) ◽  
pp. 3785-3791 ◽  
Author(s):  
Hsia-Fen Hsu ◽  
Jer-Yiing Houng ◽  
Chih-Feng Kuo ◽  
Nina Tsao ◽  
Yang-Chang Wu

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Yueh-Chiao Yeh ◽  
Tsun-Jui Liu ◽  
Hui-Chin Lai

Shikonin, a natural naphthoquinone pigment isolated fromLithospermum erythrorhizon, has been reported to suppress growth of various cancer cells. This study was aimed to investigate whether this chemical could also inhibit cell growth of lung cancer cells and, if so, works via what molecular mechanism. To fulfill this, A549 lung cancer cells were treated with shikonin and then subjected to microscopic, biochemical, flow cytometric, and molecular analyses. Compared with the controls, shikonin significantly induced cell apoptosis and reduced proliferation in a dose-dependent manner. Specially, lower concentrations of shikonin (1–2.5 μg/mL) cause viability reduction; apoptosis and cellular senescence induction is associated with upregulated expressions of cell cycle- and apoptotic signaling-regulatory proteins, while higher concentrations (5–10 μg/mL) precipitate both apoptosis and necrosis. Treatment of cells with pifithrin-α, a specific inhibitor of p53, suppressed shikonin-induced apoptosis and premature senescence, suggesting the role of p53 in mediating the actions of shikonin on regulation of lung cancer cell proliferation. These results indicate the potential and dose-related cytotoxic actions of shikonin on A549 lung cancer cells via p53-mediated cell fate pathways and raise shikonin a promising adjuvant chemotherapeutic agent for treatment of lung cancer in clinical practice.


2013 ◽  
Vol 5 (4) ◽  
pp. 1261-1265 ◽  
Author(s):  
FEIFEI LIU ◽  
DONGLEI LIU ◽  
YANG YANG ◽  
SONG ZHAO

Sign in / Sign up

Export Citation Format

Share Document